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Objective: Cross-sectional studies suggest the association between diabetic nephropathy and the PPARγ2
Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 (PPARγ2). Prospective data are
limited to microalbuminuria and no information on renal function is available to date. The present study
evaluates the association between the Pro12Ala polymorphism of PPARγ2 and the progression of albuminuria
and decay in glomerular filtration rate (GFR) in type 2 diabetes.
Patients and measurements: We studied 256 patients with an average 5-year follow-up. Among others, urinary
albumin excretion rate (UAER) was measured on spot sample, GFR was estimated with the CKD-EPI Equation.
Results: Baseline UAER and GFR were similar for carriers or non-carriers of the polymorphism. At follow-up no
significant changes from baseline were observed for UAER or eGFR in carriers of the Pro12Ala polymorphism
whereas a significant increase in UAER [17 (11.3-37.9) versus 24.5 (13.8-49.9) μg/mg, p < 0.006)] and a significant
reduction in the eGFR (82.8 ± 14.5 versus 80.3 ± 17.3 ml/min/1.73, m2 p = 0.02), were observed in non carriers of
the Pro12Ala polymorphism. Progression of nephropathy - defined according to a combined end point of UAER
and eGFR- i.e. doubling of baseline UAER to at least 100 μg/mg, or new onset microalbuminuria, or progression
from micro to macroalbuminuria, or 25% reduction of eGFR, or annualized eGFR decline >3 ml/min/year - was
significantly less frequent in Ala carriers than non carriers (11.4% vs 35.8%; p < 0.01); HR adjusted for baseline age,
AER, eGFR, HbA1c, diabetes duration and blood pressure was 0.32 (0.12-0.80).
Conclusions: This study found that among patients with type 2 diabetes, the PPARγ2 Pro12Ala polymorphism is
protective against progression of nephropathy and decay of renal function independent of major confounders.
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The etiology of diabetic nephropathy is not fully under-
stood; while environmental factors certainly play a major
role, the familial aggregation of the disease and the dispro-
portionate prevalence among specific ethnic groups, sug-
gests that genetic factors may influence the risk of the
disease [1]. Among others the peroxisome proliferator-
activated receptor (PPARγ) gene has been associated with
the risk of diabetic nephropathy [2]. In particular the* Correspondence: emanuela1978@hotmail.it
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unless otherwise stated.Ala12 variant of the PPAR γ2 isoform has been consist-
ently associated with less insulin resistance and increased
resistance to oxidative stress [3,4]. Both conditions have
been suggested to contribute to the development and pro-
gression of diabetic nephropathy [5-7]. Moreover animal
and human studies suggest that the thiazolidinediones,
which act as PPARγ2 agonists, may reduce urinary albu-
min excretion rate (UAER) and may prevent the develop-
ment of renal injury [8], thus further supporting a role for
PPARγ2 in the phenotype diabetic nephropathy. So far
genetic association studies investigating the relation of the
PPARγ2 Pro12Ala polymorphism with diabetic nephropa-
thy have provided not entirely consistent results [9-17].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(i.e. timed urine collection versus a spot urine albumin-to-
creatinine ratio, single or repeated measures of albumin-
uria) and different ethnic composition and genetic suscep-
tibility to nephropathy of the populations studied, may
partly explain discrepancies in the findings. In addition all
these studies were cross sectional and therefore liable to
survival bias, which may further contribute to the variabil-
ity of the results [18,19]. Longitudinal studies would over-
come some of these limitations but existing evidence is
limited to one study which has shown a lower frequency
of new-onset microalbuminuria in people carriers of the
PPARγ2 Ala variant [20]. This study was performed within
the context of a randomized clinical trial designed to evalu-
ate whether ACE inhibitors and calcium-channel blockers
prevent new onset microalbuminuria in a selected group of
diabetic people with hypertension, normoalbuminuria and
no evidence of renal injury at baseline [20]. Data on renal
function were not provided in this study, furthermore, due
to selection criteria, it is not known to what extent the
findings can be extrapolated to diabetic patients at large,
including patients with more advanced renal damage. The
present work expands current knowledge by evaluating the
association of the Pro12Ala polymorphism of PPARγ2 with
the progression of urinary albumin excretion and decay of
glomerular filtration rate overtime in a clinic-based sample
of patients with type 2 diabetes, representative of the dia-
betic patients seen in clinical practice.
Patients and methods
The study participants are 256 males and females with
type 2 diabetes consecutively attending the outpatients
Diabetes Clinic of the University Hospital for the screen-
ing of diabetes complications and with two complete ex-
aminations performed at least one year apart between
January 1th 2002 and January 1th 2013. The longest
available follow-up was analyzed. Exclusion criteria were
age above 75 years, dialysis or renal transplantation,
GFR < 30 ml/min/ 1.73 m2, nephrotic syndrome (pro-
teinuria > 3 g/die), urinary tract infection or congestive
heart failure. At baseline and follow-up a full clinical
evaluation was performed according to a standard protocol,
all biochemical analyses were performed in the same la-
boratory undergoing regular external quality control. BMI
was calculated as weight (Kg) /height (m2). Supine blood
pressure was measured with standard protocol. Medication
use and smoking habits were assessed by interview.
Glycated haemoglobin (HbA1c) was measured by
HPLC. Urinary albumin and creatinine were measured on
a morning spot urine sample by immunonephelometry
and enzymatic colorimetric methods, respectively; the al-
bumin/creatinine ratio was calculated; values <30 μg/mg,
30–299 μg/mg and ≥300 μg/mg in the absence of haema-
turia were defined as normo, micro or macroalbuminuria.GFR was estimated with the Chronic Kidney Disease Epi-
demiology Collaboration (CKDEPI) Equation [21].
End points were UAER and estimated GFR. Progression
of nephropathy was defined based on the occurrence of a
composite end point including any of the followings :
doubling of baseline UAER to at least 100 μg/mg; progres-
sion from normo to microalbuminuria or from micro to
macroalbuminuria; decay of eGFR (i.e. 25% reduction
from baseline, or an annualized eGFR decline >3 ml/min
per year) [22,23].
Genomic DNA was isolated using Biorobot EZ1 Qiagen.
By polymerase chain reaction (PCR) all samples were ge-
notyped for the non-synonymous variation Pro12Ala
(rs1801282) in the first exon of PPARγ2. The oligoprimers
were tested by gradient PCR to optimize melting
temperature. Genotyping was performed by an allele-
specific amplification method using SYBR Green detection
in a Realtime ABI PRISM 7000 apparatus (PE Applied
Biosystem). In 5% of the samples genotyping was per-
formed in duplicate and was fully concordant.
The study was approved by the university hospital eth-
ics committee, informed consent was obtained from all
participants.
Statistical analysis
Data is given as mean ± standard deviation (SD) for nor-
mally distributed variables and as median and Interquartile
range (IQR) for variables showing substantial asymmetry.
Accordingly, groups were compared by unpaired or paired
Student’s t-test, or by the equivalent non parametric proce-
dures (Mann–Whitney and Wilcoxon matched pairs).
Proportions were compared by Chi-square test. The Chi-
square goodness-of-fit test was used to assess deviation
from Hardy-Weinberg equilibrium of the genotypic fre-
quency. The estimated proportions of subjects with a pro-
gression of nephropathy, as above defined, were derived
with the use of the Kaplan-Meier product limit method
and compared between groups by the Log-rank test. The
Cox regression analysis was performed to explore the
relationship between progression of nephropathy and
Pro12Ala polymorphism after adjusting for potential con-
founding factors (i.e. age, diabetes duration, glucose control
estimated by HbA1c, baseline UAER and eGFR, blood
pressure and blockers of the renin angiotensin system. Re-
sults of the Cox regression model are reported as Hazard
ratio (HR) with 95% Confidence Intervals (95% C.I.) All
tests are two sided and p-value less than 0.05 was deemed
as significant. The analyses were conducted using SPSS for
Windows 16.0.
Results
The genotype distribution was in Hardy Weinberg equi-
librium, 212 participants (82.8%) were Pro/Pro homozy-
gotes, 44 (17.2%) Pro/Ala heterozygotes, no homozygotes
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study participants were similar in the two genotype
groups. Age at onset of diabetes was 52.1 ± 9.6 and 53.6 ±
7.4 respectively in carriers or non carriers of the ala allele.
Attained age, BMI, gender distribution, diabetes duration,
glycated haemoglobin, blood pressure; UAER, eGFR and
the proportion of people with micro/macroalbuminuria
or GFR < 60 ml/min/ 1.73 m2, were comparable in the
two genotype groups as was the proportion of current
smokers, the proportion of people with retinopathy and
the proportion of patients on antihypertensive medica-
tions (Table 1). As for antidiabetic treatment the propor-
tion of people treated with diet, oral agents or insulin was
similar in the two genotype groups. No one was treated
with glitazones. The median follow-up was 5 years (IQR
3–7), similar in the two genotype groups. During the study
period UAER remained stable in the Ala carriers [15.9
(IQR 9.4-26.3) versus 18.9 (IQR 11.9-30.7) μg/mg)],
whereas a significant increase was observed in people with
the ProPro genotype [17.0 (IQR 11.3-37.9 μg/mg) versus
24.5 (IQR 13.8-49.9) μg/mg], p = 0.006 (Table 2). The esti-
mated GFR remained unchanged in Ala carriers (85.3 ±
12 vs 85.2 ± 13 ml/min/ 1.73 m2, p = ns) and declined
slightly, but significantly, in the Pro/Pro group (82.8 ±
14.5 vs 80.3 ± 17.3 ml/min/ 1.73 m2, p =0.02) (Table 2).
On average glucose control and blood pressure remained
stable overtime in both genotype groups (Table 2). The
proportion of patients with progression of nephropathyTable 1 Characteristics of the study population according
to the Pro12Ala genotype
Pro/Pro (N =212) ProAla (N = 44)
Males (%) 119 (56.1) 23 (52.3)
Age (years) 60.9 ± 4.1 60.3 ± 5.7
BMI (Kg/m2) 29.4 ± 4.0 29.6 ± 4.5
HB1Ac (%) 7.0 ± 1.5 6.9 ± 0.9
Systolic BP (mmHg) 135.3 ± 18.6 133.0 ± 27.6
Diastolic BP (mmHg) 78.4 ± 8.3 78.7 ± 15.9
Diabetes duration (years) 7.4 ± 6.3 8. 2 ± 7.3
Smokers (%) 49 (23.1) 11 (25)
With Rethinopathy (%) 49 (23.1) 12 (27.3)
Treated with diet (%) 20 (9.6) 5 (11.9)
Treated with oral agents (%) 138 (66) 29 (69.1)
Treated with insulin (%) 51 (24.4) 8 (19)
Treated with ACE or ARB (%) 155 (73.1) 29 (65.9)
Treated with Statins (%) 131 (61.8) 21 (47.7)
Microalbuminuria (%) 62 (29.2) 10 (22.7)
Macroalbuminuria (%) 8 (3.8) 2 (4.5)
GFR < 60 ml/min/ 1.73 m2 (%) 14 (6.7) 3 (7)
BP: Blood pressure UAER: Urinary albumin excretion rate; GFR: glomerular
filtration rate.was significantly lower in patients carriers of the Ala poly-
morphism (11.4% vs 35.8%; p = 0.002, log rank test). The
Cox regression analysis, performed with progression of
nephropathy as the outcome variable and genotype, base-
line age, UAER, eGFR, glycated haemoglobin, diabetes
duration and blood pressure as predictor variables, con-
firmed a significant association of the Pro12Ala poly-
morphism with a lower risk of progression of nephropathy
independent of established risk factors (HR = 0.32; 95%
CI; 0.13-0.81 for12Ala carriers vs non carriers). A different
model which included blockers of the renin angiotensin
system instead of blood pressure provided similar results
(HR = 0.30; 95% CI; 0.12-0.80). The Kaplan–Meier curve
for progression of nephropathy in the two genotype
groups is given in Figure 1.
Discussion
The study conducted in a representative sample of pa-
tients with type 2 diabetes, shows that the Pro12Ala poly-
morphism of PPARγ2 is associated with a significantly
lower progression of UAER, a significantly lower decay of
GFR, significantly less overall renal damage,- as indicated
by the lower incidence of a combined end point of clinic-
ally relevant progression of albuminuria and loss of renal
function – as compared with carriers of the wild-type Pro/
Pro genotype. To our knowledge this is the first study
reporting on renal function overtime in relation to the
Pro12Ala polymorphism of PPARγ2. Major risk factors for
the progression of diabetic nephropathy such as diabetes
duration, male sex and smoking habits were comparable
in the two genotype groups, as well as age, baseline blood
pressure, glucose control (HbA1c), UAER and eGFR, thus
ruling out a confounding effect of these variables.
A lower progression of albumin excretion rate in car-
riers of the Ala allele is in line with the results of most,
though not all, cross sectional studies, and recent meta-
analyses reporting a lower prevalence of renal damage de-
fined as increased UAER in carriers of the Ala allele [9-17]
and is also coherent with results of the BENEDICT trial
showing that in hypertensive diabetic patients with no evi-
dence of renal injury at baseline, the Ala allele protects
from new-onset microalbuminuria [20]. The present study
expands current knowledge by providing data on progres-
sion to macroalbuminuria and decay of GFR over time
which represent markers of more advanced stages of dia-
betic nephropathy. In addition the representativity of the
study population makes the finding generalizable to the
diabetic population at large.
To explore the mechanisms of the protection conferred
by the Pro12Ala polymorphism of PPARγ2 is beyond the
aims of the study and we can only speculate. Although
PPARγ2 is generally perceived as a renoprotective factor
in type 2 diabetes, how PPARγ2 exerts its favourable ef-
fects remains unclear. Both systemic and organ-specific
Table 2 Glomerular filtration rate (GFR), Urinary albumin excretion rate (UAER), glycemic control and blood pressure at
baseline and follow-up according to genotype
Pro/Pro ProAla
Baseline Follow-up Baseline Follow-up
UAER (μg/mg) 17.1 (11.3-37.9) 24.5 (13.8-49.9)* 15.2 (9.4-26.3) 18.9 (11.9-30.7)
GFR (ml/min/ 1.73 m2) 82.8 ± 14.5 80.3 ± 17.3* 85.3. ±13.4 85.2 ± 13#
HbA1c (%) 7.0 ± 1.5 7.1 ± 1.4 6.9 ± 0.9 7.1 ± 0.8
PAS (mmHg) 135.3 ± 18.6 138.4 ± 22.5 133.0 ± 27.6 138.6 ± 23.1
PAD (mmHg) 78.4 ± 8.3 78.3 ± 10 78.7 ± 15.9 79.1 ± 12.6
*p < 0.05 vs baseline; # p < 0.05 vs Pro/Pro genotype.
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the systemic level PPARγ activation induces complex
metabolic effects including improved insulin sensitivity,
reduction of plasma glucose and blood pressure increased
plasma adiponectin and reduced levels of circulating non
esterified fatty acids (NEFA) and insulin-desensitizing cy-
tokines [24].
Prior studies have suggested that carriers of the 12 Ala
allele show significantly improved insulin sensitivity and
protection from diabetes as compared with wild type Pro/
Pro homozygotes [3,5]. In addition the Ala 12 variant has
been associated with an increased resistance to oxidative
stress resulting from overproduction of reactive oxygenFigure 1 Kaplan Meyer curves for progression of nephropathy (cumulaspecies under hyperglycemic conditions [4]. Both insulin
resistance and oxidative stress have been suggested as de-
terminants of the development and progression of diabetic
nephropathy.
Based on these evidence, one likely, and conceivably
causal, mechanism through which the the alanine variant
of PPARγ2 may exert renal protective effects is via re-
duction of insulin resistance and oxidative stress.
Furthermore multiple renal cell lines (glomerular mesan-
gial cells, podocytes, tubular epithelium, microvasculature)
have endogenous PPARγ expression and there is evidence
that activation of PPARγ expressed in the kidney itself
may provide additional benefits by reducing mesangialtive hazard) according to the Pro12Ala of PPARγ2 polymorphism.
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number and function and limiting interstitial infiltration of
monocytes/macrophages [25]. The hypothesis that the
renoprotective properties of PPARγ may be partly inde-
pendent of metabolic effects is further supported by studies
showing that the PPARγ agonists thiazolidinendiones at-
tenuate progression of renal damage in diabetic nepropathy
as well as in nepropathies not associated with metabolic
abnormalities, including toxic and immune mediated renal
injury [26-28]. Whether the Ala variant impacts on the ex-
pression and activity of PPAR γ at the renal level is unex-
plored and it is worth investigating.
In conclusion results of this study show a differential
susceptibility to progression of diabetic nephropathy and
loss of renal function in carriers or non carriers of the
Pro12Ala polymorphism of PPAR γ2. These results are
coherent with current knowledge on the role of PPARγ
on the pathophysiology of diabetic nephropathy and lend
further support to a conceivably causal association of
the Pro12 Ala polymorphism with protection from dia-
betic nephropathy.
For better interpreting the results, some study limita-
tions should be acknowledged. Firstly the small sample
size and the definition of albuminuria based on a single
measurement limited the ability to draw more solid con-
clusions, both conditions, however, are likely to bias the
findings towards null, rather than towards positive. Sec-
ondly, due the observational design the study is hypoth-
esis generating rather than conclusive. Nonetheless this
is the first report on protection from worsening of renal
function overtime in carriers of the Pro12Ala polymorph-
ism of PPAR γ2, in addition the selection of a study sam-
ple representative of the diabetic patients routinely seen in
clinical practice makes the results generalizable to the dia-
betic population at large.
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